Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Blood Adv ; 8(9): 2074-2084, 2024 May 14.
Artículo en Inglés | MEDLINE | ID: mdl-38471063

RESUMEN

ABSTRACT: Disruption of the intestinal microbiome is observed with acute graft-versus-host disease (GVHD) of the lower gastrointestinal (LGI) tract, and fecal microbiota transplantation (FMT) has successfully cured steroid-refractory cases. In this open-label, single-arm, pilot study, third-party, single-donor FMT was administered in combination with systemic corticosteroids to participants with high-risk acute LGI GVHD, with a focus on treatment-naïve cases. Participants were scheduled to receive 1 induction dose (15 capsules per day for 2 consecutive days), followed by 3 weekly maintenance doses, consisting of 15 capsules per dose. The primary end point of the study was feasibility, which would be achieved if ≥80% of participants able to swallow ≥40 of the 75 scheduled capsules. Ten participants (9 treatment-naïve; 1 steroid-refractory) were enrolled and treated. The study met the primary end point, with 9 of 10 participants completing all eligible doses. Organ-specific LGI complete response rate at day 28 was 70%. Initial clinical response was observed within 1 week for all responders, and clinical responses were durable without recurrent LGI GVHD in complete responders. Exploratory analyses suggest that alpha diversity increased after FMT. Although recipient microbiome composition never achieved a high degree of donor similarity, expansion of donor-derived species and increases in tryptophan metabolites and short-chain fatty acids were observed within the first 7 days after FMT. Investigation into the use of microbiome-targeted interventions earlier in the treatment paradigm for acute LGI GVHD is warranted. This trial was registered at www.ClinicalTrials.gov as #NCT04139577.


Asunto(s)
Trasplante de Microbiota Fecal , Enfermedad Injerto contra Huésped , Humanos , Enfermedad Injerto contra Huésped/terapia , Enfermedad Injerto contra Huésped/etiología , Trasplante de Microbiota Fecal/métodos , Masculino , Femenino , Persona de Mediana Edad , Adulto , Microbioma Gastrointestinal , Anciano , Proyectos Piloto , Enfermedad Aguda , Resultado del Tratamiento
2.
NEJM Evid ; 1(11): EVIDmr2200210, 2022 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-38319853

RESUMEN

A 67-Year-Old Man with Pruritus and DyspneaThis report tells the story of a 67-year-old man presenting with itching on his back and shortness of breath. Recently diagnosed with metastatic tonsillar squamous cell carcinoma, he came to the oncology clinic to receive a chemotherapy infusion. Using questions, physical examination, and testing, an illness script for the presentation emerges; the differential is refined until a final diagnosis is made.


Asunto(s)
Disnea , Prurito , Masculino , Humanos , Anciano , Disnea/diagnóstico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA